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Abstract:
Alzheimer’s Disease (AD) is a neurodegenerative disease that is characterized by amyloid-beta
(Aβ) plaques, neurofibrillary tangles, neuronal death, and profound cognitive impairment.
Previous studies have indicated that increased Aβ and alterations in the daily sleep-wake cycle
are early risk factors and possible predictors of AD. Acute sleep deprivation decreases Aβ
clearance, and increased Aβ levels stimulate neuroinflammation and accelerate loss of neurons
and synapses. Likewise, it has been shown that there are higher rates of sleep disorders in AD
patients. However, limited studies have investigated whether sleep fragmentation accelerates the
progression of AD pathology. This partial review will discuss experiments investigating the link
between sleep and AD. Additionally, we completed three pilot studies exploring whether chronic
disruption of daily sleep-wake cycles with sleep fragmentation (SF) increases Aβ and
neuroinflammation in the brains of transgenic mice that serve as an experimental model for AD.
Mice were sorted into an undisturbed sleep (US) group and an SF group, involving stimulation
for one-hour periods during the light phase, 4 times/day, 5 days/week for 4 weeks. Sleep
monitoring using the noninvasive piezoelectric system showed that the US mice slept as
expected during the light phase; however, SF mice had greatly reduced sleep during the SF
intervals, and sleep loss was only partially restored during the dark period. Protein analysis
showed that hippocampal levels of Aβ40 and Aβ42 were significantly increased in SF compared
to US mice. Additionally, gene expression markers of neuroinflammation in the hippocampus
were significantly elevated in SF mice. These results suggest that fragmentation of the daily
sleep-wake cycle stimulates hippocampal levels of Aβ and neuroinflammation. If future rodent
studies support these findings that chronic SF advances AD pathology, then improving sleep
consolidation would be a potential therapeutic strategy for reducing the progression of AD in
humans.

For years, it has been known that there is an important link between sleep and
neurodegeneration. We may know from experience that even one night of poor sleep can cause
our cognitive function to decline. The past two and a half years, I have worked in a research lab
testing the effects of sleep fragmentation on the progression of Alzheimer’s disease (AD) in a
mouse model. Before I go over the methods and results of these experiments, I will go into depth
about the background of sleep, AD, and other studies that have found similar results showing the
interconnectedness of sleep and AD.
Part I: Literature Review of Sleep and Alzheimer’s Disease
We spend nearly one-third of our lives sleeping, so clearly sleep must be an important
physiological process. Additionally, while the amount of sleep may differ between species,
almost every animal sleeps, including mammals, birds, reptiles, amphibians, and some insects
and fish (Hobson et al., 2005). Despite the universality of sleep, it is still somewhat of a mystery
why we sleep. For a while, scientists believed that sleep was a time of greatly reduced brain
activity; however, with the discovery of rapid eye movement (REM) sleep, they realized that the
brain is very much active during sleep, and may control many important processes (Hobson et
al., 2005). Sleep is divided into REM sleep and non-rapid eye movement (NREM) sleep, which
is further divided into 3 stages: N1, N2, and N3. Scientists use electroencephalography (EEG),
which records electrical activity of the brain, electromyography (EMG), which records muscle
activity, and electrooculography (EOG), which measures eye movements, to differentiate among
the different sleep stages. One first enters N1 sleep from wake, where EEG waves begin to slow
in frequency, and EMG and EOG activity is low, but still present. One progresses through N2
into N3 sleep, which is labelled as slow wave sleep due to the presence of very low frequency
(0.5-4 Hz) and high amplitude brain waves. EOG and EMG activity are very low in N3. Slow
wave sleep is longest towards the beginning of the night while REM sleep lengthens towards the
end of the night. REM sleep is characterized by a very active brain, as illustrated by high
frequency waves on the EEG. It can be distinguished from wake because muscles are paralyzed
during REM sleep, so there is no EMG activity, and eye movements are very rapid (hence the
name rapid eye movement sleep), as shown by increased activity in the EOG. Each sleep cycle
through NREM and REM sleep lasts about 90 minutes. We complete sleep cycle after cycle
throughout the night, preferably passing through four to six cycles a night, until we awaken,
normally out of REM or light sleep. Rodents also show sleep cycles, but they are much shorter
than in humans, only lasting about 1-2 minutes. These short sleep cycles are called sleep bouts,
and rodents have many sleep bouts throughout the 24-hour day, with increased numbers of sleep
bouts during the light phase, or rest period in nocturnal rodents.
There have been many studies addressing the importance of sleep in general and the
purpose or function of REM and NREM sleep. One theory of why we sleep is that sleep drives
metabolic clearance from the brain. According to this hypothesis, without sleep, harmful
substances would build up in the brain and cause problems, such as neurodegeneration. One
study that backs up this theory with evidence is from Xie et al. (2013). The brain doesn’t have a
conventional lymphatic system; instead, it has a glymphatic system, which describes the
convective exchange between the cerebrospinal fluid (CSF) and interstitial fluid (ISF). CSF

circulates throughout the brain, which allows for the removal of ISF proteins, like amyloid-beta
(Aβ), a major protein involved in AD (as discussed later). This study by Xie et al. (2013)
hypothesized that the sleep-wake cycle regulates glymphatic clearance and Aβ clearance is
increased during sleep. Using a fluorescent tracer, they discovered that CSF influx is suppressed
in conscious/awake mice, meaning less CSF enters the brain and exchanges with ISF.
Additionally, Aβ was cleared two times faster in sleeping mice compared to awake mice. This
supports the theory that sleep is essential for glymphatic clearance of harmful proteins from the
brain.
Another proposed function of sleep is that it helps consolidate memories and improves
learning. One study looked at how early nocturnal sleep, dominated by slow wave sleep, and late
nocturnal sleep, dominated by REM sleep, affected the consolidation of declarative and
procedural memory (Plihal and Born, 1997). Declarative memory is long-term memory
associated with facts and experiences while procedural memory is long-term memory associated
with performance of tasks without conscious awareness. This study asked healthy men to recall a
paired-associate word list (task of declarative memory) and complete a mirror-tracing task (task
of procedural memory). Results compared how participants did on each task after wakefulness,
early nocturnal sleep, and late nocturnal sleep. Early sleep increased recall of the declarative
memory task compared to late sleep, and both were improved compared to wakefulness.
Additionally, late sleep improved performance on the procedural memory task compared to early
sleep, and both were improved compared to wakefulness. Therefore, this study showed not only
that sleep is important for memory consolidation and learning, but that NREM sleep specifically
helps improve declarative memory to a higher degree while REM sleep helps improve
procedural memory to a greater degree (Plihal and Born, 1997).
Finally, other proposed purposes of sleep include theories related to energy conservation
because metabolism is greatly reduced during sleep. One of these theories is the restorative
theory, which was proposed because muscle growth, tissue repair, protein synthesis, and growth
hormone release occur mainly during sleep. The other is the brain plasticity theory, which states
sleep helps brain development and maintenance through synaptic growth and pruning (Tononi
and Cirelli, 2003; Tononi and Cirelli, 2014).
Now that the basics of sleep have been covered, we will dive into the fundamentals of
Alzheimer’s disease (AD). AD affects millions of people, and there is no known cure for it yet.
What used to be a mysterious disease has been researched extensively, and we now know some
information about its mechanism of action and risk factors. As many people are aware, signs of
AD can include memory loss, aphasia (language disturbance), apraxia (impaired motor function),
agnosia (failure to recognize objects despite intact sensory functioning), forgetfulness,
disorientation/confusion, and disturbance in organization/planning for future events (Schachter
and Davis, 2000). At the pathological level, AD is characterized by amyloid-beta (Aβ) plaques
and neurofibrillary tangles in the brain, as well as loss of synapses and eventually, neuronal
death. Aβ plaques are deposits of insoluble Aβ, which is a protein generated from the amyloid
precursor protein (APP). APP can get cleaved along two pathways: the non-amyloidogenic
pathway and the amyloidogenic pathway. The non-amyloidogenic pathway involves the enzyme

α-secretase cleaving APP into sAPPα and C83, which is then cleaved by γ-secretase to create p3
and AICD. These molecules are not pathogenic. The amyloidogenic pathway uses the enzyme βsecretase instead to cleave APP to sAPPβ and C99. C99 is cleaved by γ-secretase to form Aβ and
AICD (Soria Lopez et al., 2019). It is this Aβ peptide that can aggregate and cause problems in
AD patients. γ-secretase can cleave at variable spots along C99, producing Aβ with varying
lengths, from 37 to 42 amino acids. The longer the variants, especially Aβ40 and Aβ42, the more
toxic they are because they are more likely to aggregate into plaques (Soria Lopez et al., 2019).
The accumulation of Aβ causes many downstream effects to occur, such as the hyperphosphorylation of tau protein. This hyperphosphorylated tau is what makes up neurofibrillary
tangles, another hallmark of AD, and results in neuronal death due to neurofibrillary tangles
blocking neurons from effectively communicating with each other. Aβ is also toxic because it
causes inflammation, oxidative stress, and excitotoxity. Ultimately, the formation of senile Aβ
plaques and neurofibrillary tangles leads to neuronal death, synapse loss, and the progression of
AD. Typically, there is accelerated neuronal death in the hippocampus and entorhinal cortex first
in AD patients (Schachter and Davis, 2000). These brain areas correspond to those involved in
memory and learning, giving rise to the common AD symptoms of impaired learning and
memory. Ventricles, fluid-filled spaces within the brain, grow larger as the hippocampus and
other brain areas shrink. Next, neuronal death will occur in the cerebral cortex, which is
responsible for language, reasoning, long-term memory storage, and social behavior, causing a
variety of impairments. As time goes on, more neurodegeneration spreads to other brain areas
and results in death.
There are several genes and risk factors involved with developing AD. Three mutations
were identified in patients with familial early-onset autosomal dominant AD, but these mutations
account for fewer than 1% of all AD cases (Schachter and Davis, 2000). These mutations are in
the APP, presenilin-1, and presenilin-2 genes, which all cause an increase in the amount of Aβ42
produced (Homolak et al., 2018). The fourth gene that increases the risk of developing AD is
apolipoprotein E (APOE) (Schachter and Davis, 2000). One allele of this gene, APOE4, has been
shown to increase one’s risk of AD, and many patients with both early and late-onset AD have
this allele. It is thought that APOE4 enhances Aβ aggregation or decreases its clearance from the
brain, leading to AD pathology (Soria Lopez et al., 2019). Finally, another risk factor is age—as
one gets older, their chances of developing AD increase substantially.
Next, let’s explore how sleep changes in individuals with AD. One of the main reasons
AD patients are institutionalized is due to sleep-wake disturbances, including sundowning and
nocturnal wandering (Ju et al., 2013). Sundowning describes the restlessness, confusion, and
irritability of AD patients as daylight begins to fade, sometimes continuing into the night. This
makes it difficult for AD patients to fall asleep and stay in bed. In mild to moderate AD, sleepwake disturbances such as increased inadvertent daytime napping and insomnia at night affect
25-40% of patients (Ju et al., 2013). Wakefulness after sleep onset (WASO) and sleep latency, or
amount of time it takes to fall asleep, increase as AD progresses, and total sleep time often
decreases (Peter-Derex et al., 2015). Even more importantly, the pattern of sleep changes to
become very fragmented, with less consolidated sleep in the evening and excessive tiredness
during the day, which can result in multiple naps. A study by Ju et al. (2013) was conducted to

determine how Aβ deposition in preclinical AD affects sleep quality and quantity. Preclinical AD
refers to the period of pathological changes characteristic of AD (such as increased Aβ) but
before cognitive symptoms have arisen; it has been found that increased levels of Aβ and tau as
well as impaired sleep precludes the arrival of cognitive decline symptoms in AD patients by as
many as 10-20 years (Wang and Holtzman, 2019). This study (Ju et al., 2003) used 142
cognitively normal adults aged 45+ and measured their sleep with actigraphy, which is a sensor
on one’s wrist that monitors rest and activity. They also measured the amount of Aβ42 in the
cerebrospinal fluid (CSF), where the less Aβ that is detected in the CSF means more Aβ is
accumulating into plaques in the brain instead of being cleared. The 32 participants with amyloid
deposition had worse sleep quality as measured by decreased sleep efficiency (percentage of
time in bed spent asleep) compared to those without amyloid deposition. Their WASO was also
increased, again showing their poorer sleep quality. Additionally, frequent daytime napping (3+
days per week) was significantly associated with amyloid deposition.
Another study by Musiek et al. (2018) found similar results when looking at how the
circadian rest-activity pattern changes in preclinical AD. Cognitively normal adults wore
actigraphs to measure their rest and activity patterns, and the experimenters also quantified the
amount of Aβ (both Aβ42 and plaques) and phosphorylated tau. Individuals with amyloid
deposition had significantly more circadian fragmentation as measured by intradaily variability.
In other words, these individuals showed an abnormal circadian rhythm with increased nighttime
activity and decreased daytime activity. Furthermore, increased CSF levels of phosphorylated tau
compared to Aβ42 is a marker of neurodegeneration. This study found that increasing this ratio
of phosphorylated tau to Aβ42 was associated with an increase in circadian fragmentation. Once
again, this supports the idea that sleep and AD are interconnected—those with AD have altered
sleep and circadian rhythms, and this alteration can be seen years before the cognitive symptoms
of AD begin. Furthermore, clinical follow up studies have shown that cognitively normal older
individuals with high sleep fragmentation had a 1.5-fold increased risk of developing AD while
self-reported reduced sleep was associated with a 2-fold increased risk of AD development
(Holth et al., 2017). Additionally, worse sleep efficiency and diminished slow wave sleep (SWS)
duration are associated with rate of future Aβ accumulation (Winer et al., 2020). This begs the
question if sleep plays a causal role in AD pathology and progression, which is what my lab
investigates—this will be discussed further below in Part II.
Many studies have shown a bidirectional relationship between sleep alterations and AD
progression. Besides poor sleep leading to AD, AD can also contribute to poor sleep. As neurons
die and synapses are lost in AD brains, important brain areas for sleep may be degenerated. For
instance, loss of cholinergic neurons in the basal forebrain or noradrenergic neurons in the locus
coeruleus could affect sleep-wake regulation (Holth et al., 2017). AD can make sleep problems
worse for patients due to the destruction of brain areas essential for proper sleep. However, as
mentioned above, sleep changes are often seen 15-20 years before AD symptoms begin (Wang
and Holtzman, 2019); therefore, it is likely that sleep problems may lead to the progression of
AD, and as AD progresses further, it worsens patients’ sleep, creating a vicious cycle.

Several studies have shown that sleep deprivation and fragmentation cause increased
levels of Aβ and tau to accumulate in the brain, which can lead to the progression of AD. Here,
we will explore the specifics of some of these studies that aimed to determine a causal link
between sleep and AD. The first study was done by Kang et al. (2009), and they monitored
hippocampal levels of Aβ in mice expressing a mutated form of human APP that was known to
be associated with AD. First, they looked at how Aβ levels fluctuate through the light/dark cycle.
During the night when mice are more active, levels of Aβ are higher; on the contrary, during the
light phase when mice tend to sleep more, levels of Aβ are lower. This is the normal, diurnal
pattern of Aβ caused by the sleep-wake cycle, and it is likely due to the increased clearance of
Aβ observed during sleep. Next, experimenters exposed these mice to six hours of sleep
deprivation at the beginning of the light phase. This caused mice to have significantly higher
levels of ISF Aβ compared to those not sleep deprived. Additionally, when the sleep deprived
mice were allowed to have rebound sleep, their Aβ levels were reduced. Finally, since one
instance of sleep deprivation caused significantly increased Aβ levels, experimenters were
interested in what chronic sleep deprivation would do to Aβ levels in the hippocampus. Mice
were sleep deprived for twenty hours a day for 21 days; after those 21 days, sleep deprived mice
showed a significant increase in Aβ plaque formation, supporting the hypothesis that sleep
deprivation can directly impact Aβ levels and AD progression.
Another study by Minakawa et al. (2017) investigated the effects of chronic sleep
fragmentation on Aβ deposition in the APP/PS1 mouse model of AD. Sleep fragmentation was
carried out by allowing mice access to a running wheel in cages with a low volume of water in
the bottom. In order to avoid the water, the mice had to sit or run on the wheel. This housing
condition altered the sleep/wake pattern of the mice as evidenced by their increased activity
during the light phase (when mice are normally less active) and decreased activity during the
dark phase (when mice are normally more active). This sleep fragmentation induced in the mice
resembles the sleep fragmentation seen in human AD patients who sleep more during the day
and have frequent nighttime awakenings. The sleep fragmentation protocol resulted in mice
having significantly more Aβ plaque load, including larger plaques and an increased number of
plaques in the brain, compared to control. Moreover, this effect was dose-dependent—the greater
the sleep fragmentation, the greater the Aβ plaque load.
Ju et al. (2017) aimed to determine how disrupted slow wave sleep (SWS) specifically
affects Aβ levels in human CSF. 17 participants slept in the lab and were awoken once the EEG
indicated they were in SWS/N3. Those participants that had SWS disruption showed greater
increases in levels of Aβ40 and Aβ42 compared to those who slept through the night without any
disruption. This study also discovered that participants with worse sleep quality at home, as
measured by actigraphy for 6 days, had increased levels of hyperphosphorylated tau, another
marker of AD.
Qiu et al. (2016) investigated the effects of chronic sleep deprivation on AD pathology as
well as learning and memory in the APP/PS1 mouse model of AD. Mice underwent two months
of chronic sleep deprivation (SD) for four hours each day, and experimenters found that chronic
SD increased senile Aβ plaque deposition as well as insoluble levels of Aβ in the hippocampus

and cortex. This effect was even long-lasting when tested again at 3 months post-experiment.
Additionally, chronic SD increased levels of hyperphosphorylated tau, which also persisted out
to 3 months. Interestingly, the study found that chronic SD caused mitochondrial dysfunction
and neuronal apoptosis in the hippocampus, leading the experimenters to believe this may be the
mechanism by which SD acts to induce pathological changes in the brain. Finally, the study also
looked at how SD affected learning and memory using an operant learning chamber with four
corners. A water bottle was placed in one corner and mice were trained to go to that corner and
“nosepoke” for a drink. Later, the water was placed in a different corner of the chamber and the
frequency of correct and incorrect visits along with nosepokes were counted. Chronic SD
resulted in more incorrect visits and nosepokes. This study painted a wonderful picture of how
sleep deprivation increases levels of Aβ and tau, causes neuronal death, and even detrimentally
impacts spatial learning and memory in a mouse model of AD.
Finally, Lim et al. (2013) ran a large study investigating if sleep fragmentation increases
one’s risk of developing AD. 737 people without dementia wore actigraphs for ten days to
measure their sleep and activity and were followed for up to six years to determine the
prevalence of AD. Experimenters measured sleep fragmentation using kRA, which is the
probability per 15 second epoch of having an arousal after at least five minutes of sleep; thus, a
higher kRA would mean greater sleep fragmentation. After the follow-up, 97 people (13%)
developed AD, and the sleep fragmentation metric kRA was positively associated with the risk of
developing AD. An individual with high (90th percentile) sleep fragmentation had a 1.5-fold
increased risk for developing AD as compared to an individual with low (10th percentile) sleep
fragmentation. Likewise, increased kRA was associated with lower baseline cognitive
performance and a more rapid rate of cognitive decline. This study was instrumental in
establishing sleep fragmentation as a risk factor for AD. It joins the studies mentioned above in
illustrating the relationship between disrupted/fragmented sleep and AD neuropathology, such as
Aβ and tau.

Part II: Methodology and Results of Our Three Pilot Studies
There has been a great deal of growth in the sleep and AD research fields, as evidenced
by the studies described above; however, limited studies have shown a causal relationship and
investigated whether sleep fragmentation accelerates the progression of AD pathology. We
completed three pilot studies exploring whether chronic disruption of daily sleep-wake cycles
with sleep fragmentation (SF) increases Aβ and neuroinflammation in the brains of transgenic
mice that serve as an experimental model for AD.
Methods:
Experimental Animals and Housing Conditions:
All three pilot studies used 16 female 3xTg-AD mice since females have been shown to
be at increased risk for AD as well as show more symptoms than males (Ju et al., 2013). The
3xTg-AD mouse model expresses 3 dementia-related mutations in amyloid precursor protein

(APP), presenilin 1, and tau, resulting in this mouse model developing Aβ plaques and
neurofibrillary tangles (Oddo et al., 2003). The Aβ plaques develop first, around 4 months, and
continue to increase as the mice age; tau pathology occurs later, at around 12 months (Oddo et
al., 2003; Sterniczuk et al., 2010). The mice were kept on a 12:12-hr light/dark cycle with lights
on at 7:00 am and lights off at 7:00 pm (19:00). Food and water were provided ad libitum. Mice
were group housed with 4 mice/cage during weeks 2 and 3 of the experiment when sleep
recording via the piezoelectric system was not happening; however, during the one-hour sleep
fragmentation intervals, SF mice were singly housed and then returned to group housing when
the SF interval was complete. During weeks 1 and 4, all mice were singly housed in the
piezoelectric system setup to measure sleep, which will be discussed more in depth below. The
three pilot studies (called SF studies) used female 3xTg-AD mice of different ages: SF 2 used 8month-old mice, SF 3 used 11-month-old mice, and SF 4 used 14-month-old mice.
Experimental Design:
The three SF studies each ran for a total of 4 weeks. The 16 mice were randomly split
into 2 groups, an undisturbed (US) group and an SF group, with 8 mice in each group. The SF
group underwent SF intervals that were one hour long and occurred 4 times a day, 5 days a week
(Monday-Friday). These SF intervals were equally spaced throughout the light phase, occurring
from 9:00-10:00 am, 11:30 am-12:30 pm, 2:00-3:00 pm, and 4:30-5:30 pm. During these SF
intervals, the SF mice were kept awake by placing novel toys in their cages or gently tapping the
mice with a paintbrush; meanwhile, the US mice were left undisturbed. We did sleep
fragmentation this way to best match the sleep profile of human Alzheimer’s patients. Many
Alzheimer’s patients show fragmented/disrupted sleep across the night (normal rest phase),
which is what we are mimicking with SF during the light phase, when mice prefer to be asleep.
After the 4 weeks of SF were over, all mice were euthanized between 5:30-7:30 pm using CO2
and decapitated. The brains were dissected and right and left regions of the hippocampus and
cerebral cortex were kept for further analysis. One side was used for protein analysis while the
other side was used to detect expression of neuroinflammatory markers.
Sleep Monitoring:
Sleep was monitored noninvasively during the first and fourth weeks of each study via
the piezoelectric system (Signal Solutions; Lexington, KY). This involves a sensor placed
beneath the cages of individual animals that can transform mechanical pressure into electrical
signals (Mang et al., 2014). The sensors are very sensitive to vibration and can even detect the
rhythmic breathing of mice at ~3 Hz. Awake and active mice that are grooming, eating, running,
etc. show high amplitude and frequency waves that are more erratic/irregular in nature. However,
mice that are asleep show very regular waves that are low in amplitude and have a frequency of
about 3 Hz. The piezo system computes a “decision statistic” for every 2-second interval where a
high value indicates a regular signal and the mouse is most likely asleep and a low value
indicates an irregular signal and the mouse is most likely awake. An overall decision statistic
threshold is computed based on the saddle point of the distribution of decision statistics collected
over time—everything above this threshold is considered sleep and everything below this
threshold is considered wake. Mang et al. (2014) compared results from the piezoelectric system

to the typical way of monitoring sleep through EEG and found that the piezo system had 90%
accuracy. Since EEG is an invasive procedure that requires the surgical implantation of
electrodes into the mice’s skulls and recovery time, the piezoelectric system is an accurate,
noninvasive alternative to EEG.
Using data from the piezoelectric system, average percent daily sleep was calculated for
each mouse in addition to percent sleep in both the light and dark phases. Average sleep bout
length was also calculated for 24 hours, light phase, and dark phase. A sleep bout begins when a
30-second interval contains greater than 50% sleep and terminates when a 30-second interval
contains less than 50% sleep.
Aβ and Neuroinflammatory Marker Analysis:
In order to assess neuropathology, Aβ was extracted from brain samples and quantified.
Two forms of Aβ were measured—Aβ40 and Aβ42, with Aβ42 considered more toxic due to its
longer length and increased capability of aggregating into plaques. Additionally, two buffers—
DEA and RIPA—were used to extract Aβ from the brain samples. DEA-soluble Aβ includes
diffusible Aβ monomers and oligomers while RIPA-soluble Aβ includes aggregated Aβ. Once
the Aβ was extracted from the hippocampus and cortex brain samples, the amounts were
analyzed by sandwich ELISA, or enzyme-linked immunosorbent assay, for all three experiments.
This procedure measures the amount of antigen, or Aβ, present between two layers of antibodies,
a capture and detection antibody. The detection antibody used is fluorescent, so the concentration
of Aβ was determined based off how much fluorescence was given off by the sample. More
fluorescence indicated more Aβ present in the sample, which points to that particular mouse
having greater AD pathology.
Markers of reactive microglia, reactive astrocytes, proinflammatory cytokines, and
inflammatory chemokines were measured in the hippocampus and cortex by TaqMan low
density gene expression array in SF 2 and SF 3 mice. The TaqMan technique uses real-time PCR
to measure the mRNA expression of genes. Markers of reactive microglia were measured
because microglia are macrophages and act as the main immune cells in the brain. It is thought
that as Aβ aggregates into plaques, microglia become activated so that they can phagocytize and
get rid of this toxic protein (Song and Colonna, 2018). In early stages of AD, microglial
activation likely has positive effects in helping to clear Aβ from the brain; however, in later
stages of AD, too much microglial activation can actually be detrimental. Chronic, excessive
microglial activation can cause the excessive loss of neurons and synapses, accelerating
neurodegeneration and cognitive decline. The markers of reactive microglia that were measured
in this study included Ctsd, Cst7, and Clec7a. Reactive astrocytes were another cell measured in
this study. Astrocytes are the most abundant glial cells in the brain, and have many functions
including secretion of nutrients, maintenance of the neuronal microenvironment/homeostasis,
and regulation of the blood-brain barrier (Li et al., 2019). However, it has been found that Aβ
can disrupt the normal functioning of astrocytes, and these reactive astrocytes can be neurotoxic
and produce inflammatory cytokines and reactive oxygen species; thus, this leads to even more
neuroinflammation and neurodegeneration (Li et al., 2019). The specific markers of reactive
astrocytes measured in this study included GFAP, LCN2, and PTX3.

In addition to microglia and astrocytes, signaling molecules involved in inflammation
were measured, including inflammatory cytokines and chemokines. Proinflammatory cytokines
are recruited by the immune system when it is activated. This activation can be in response to a
foreign invader or, in the case of AD, an accumulation of the toxic protein Aβ. With increased
release of cytokines, more immune cells and inflammatory molecules are recruited to the brain,
causing neuroinflammation to worsen, leading to neurodegeneration (Song and Colonna, 2018).
Several markers of important proinflammatory cytokines were measured in this study, including
tumor necrosis factor alpha (TNF-α), interleukin (IL)-6, and IL-1β. Finally, markers of
inflammatory chemokines, including CCL2, CCL3, and CXCL1, were measured. Chemokines
are a family of cytokines that play a role in the regulation of the immune system. When
functioning properly, they are involved in cell communication/signaling and recruiting immune
cells to the site of infection or damage; however, they can become over-active in AD and cause
neuroinflammation (Martin and Delarasse, 2018). Chemokines can increase the production of Aβ
as well as recruit T cells and over-activate microglia in the brain, leading to neuroinflammation
and neuronal death (Martin and Delarasse, 2018).
Results:
Effects of SF on Sleep:
Four time periods were analyzed for sleep differences: baseline, week 1 SF, recovery, and
week 4 SF. Baseline was the mice’s normal sleep as measured by the piezoelectric system on the
weekend prior to the first SF shift. Week 1 and 4 SF was the sleep measured during the first and
fourth weeks of the SF protocol respectively
(Monday-Friday) when mice were in their
piezo cages. Recovery is the weekend of rest
between weeks 3 and 4 of the SF study when
mice were moved from group housing into
piezo cages for sleep recording. The data
showed a large reduction in sleep for the SF
mice during their sleep fragmentation
intervals compared to the US mice (Figure 1).
This proves that our SF protocol was
successful in keeping SF mice awake during
the four SF intervals a day while not overly
disturbing the US mice. Figure 1 shows that
the US mice slept as expected during the 24Figure 1. Chronic sleep fragmentation alters the daily sleep
profile. Values represent the mean ± SEM sleep percentage
for 30 min bins. This data was taken from SF 2 during weeks 1
and 4 as an average of mice in each group across the 5 days of
the SF protocol. SF 3 and 4 graphs look very similar so are not
shown here. N=8/group. Horizontal white and black bars at
the bottom indicate the light and dark phases respectively.

hour day, with about 50-70% sleep during the light phase, or active phase, and about 30-40%
sleep during the dark phase, or rest phase. Additionally, Figure 1 shows areas where the SF mice
attempt to make up for the sleep loss they incurred from the SF intervals. Inter-fragmentation
intervals represent the times during the light phase between the SF intervals, including 10:0011:30 am, 12:30-2:00 pm, and 3:00-4:30 pm. SF mice experience an increase in sleep during
these inter-fragmentation periods, especially by week 4 of SF (Figure 1, Table 1). Additionally,
SF mice tend to sleep more than the US mice during the dark phase (when mice are normally
active) to make up for their sleep loss. This shows the homeostatic control of sleep, or sleep
rebound. The SF mice would like to sleep during the light phase, however our protocol forbids
this during certain intervals; as a result, the SF mice have a build up of sleep need and
compensate for this by sleeping more during inter-fragmentation intervals and during the dark
phase by week 4 of the study.
Table 2 breaks down sleep percentages across 24 hours, dark phase, and light phase for
all three experiments (SF 2, 3 and 4) for baseline, week 1 SF, recovery, and week 4 SF. During
the first week of SF for all three experiments, SF mice had decreased sleep over 24 hours and
during the light phase compared to US mice, but there was no significant change in dark phase
sleep. The decrease in sleep was more dramatic during the light phase compared to the 24 hour
sleep—for instance, in SF 2, SF mice had decreased sleep compared to US mice by 19.2% in the
light phase and only 9.1% over 24 hours. This makes sense because the SF mice had four, onehour SF intervals during the light phase across the 5 days of the week that greatly reduced their
sleep. Any sleep made up during the dark phase would have caused the 24-hour sleep to not be
quite as decreased in SF compared to US mice.
By week 4, slightly different sleep trends are seen. In SF 2 and 3, there is no significant
change in sleep percentage during the light phase and 24 hours; instead, SF mice show a
significant increase in sleep compared to US mice during the dark phase. This data specifically
shows the power of sleep rebound. By week 4 of the experiment, SF mice are extremely sleep
deprived and will try to make up sleep during the inter-fragmentation intervals and dark phase.
This make-up sleep is why SF mice sleep 30.8% (SF 2) and 19.7% (SF 3) more in the dark phase
compared to US mice in week 4. At first glance, it may appear strange that SF mice show no
difference in sleep compared to US mice during the light phase even though sleep fragmentation
intervals were still occurring. The reason behind this is that even though the SF mice had four,
one-hour intervals of sleep deprivation during the light phase, they would immediately fall asleep
during the other hours of the light phase, especially the inter-fragmentation intervals (Table 1).
As stated above, these inter-fragmentation intervals occur between SF sessions, Monday through
Friday from 10:00-11:30 am, 12:30-2:00 pm, and 3:00-4:30 pm. Specifically in SF 3, the SF
mice showed a 21.4% increase in sleep compared to US mice during the inter-fragmentation
intervals of week 4 (p=0.0009). This resulted in the lack of significant difference between light
phase sleep in SF and US mice in SF 2 and 3. These younger SF mice (8 months old and 11
months old) changed their distribution of sleep across the light and dark phases while keeping
their total, 24-hour amount of sleep similar, in response to the SF protocol.

However, the older 14-month-old mice of SF 4 had difficulty in adjusting their
distribution of daily sleep in response to the SF protocol. By week 4 of SF 4, the SF mice still
had decreased light phase sleep and only showed an insignificant increase in dark phase sleep.
This means that the SF mice were kept awake during the SF intervals in the light phase and
couldn’t recover this sleep during the inter-fragmentation intervals. In fact, there was only a
1.9% increase in sleep in the SF mice compared to US mice during the inter-fragmentation
intervals of week 4 for SF 4, and this was insignificant, proving the lack of rebound sleep in SF
mice during these time intervals (Table 1). Moreover, the insignificant increase in dark phase
sleep in SF mice of SF 4 compared to US mice shows that SF mice had trouble adjusting their
daily sleep distribution to recover lost sleep from the SF sessions, and this could be due to their
increased age.
Table 1. Sleep Percentage Data during the Inter-fragmentation Intervals. Interfragmentation intervals occur between SF sessions, Monday through Friday from
10:00-11:30 am, 12:30-2:00 pm, and 3:00-4:30 pm. Data is shown for each pilot
study on weeks 1 and 4 when piezoelectric sleep was recorded, N=8/group.

The youngest mice at 8 months old (SF 2) may have adjusted their sleep best in response
to the SF protocol compared to the others. This is evident when looking at the recovery weekend
between weeks 3 and 4 of the SF protocol (Table 2). The SF mice from SF 2 were the only SF
mice out of all the experiments that showed a significant increase in dark phase sleep and 24hour sleep compared to US mice. This proves that they had already adjusted their sleep by the
recovery weekend instead of waiting until week 4 to adjust (like in SF 3) or not adjusting well at
all (like in SF 4).

Table 2. Sleep Percentage Data for SF 2, 3 and 4.
Values represent mean ± SEM. N=8/group.
SF 2 (8-month-old mice)
Sleep %
24-hours
Dark phase
Light phase

24-hours
Dark phase
Light phase

Sleep %
24-hours
Dark phase
Light phase

24-hours
Dark phase
Light phase

Sleep %
24-hours
Dark phase
Light phase

24-hours
Dark phase
Light phase

Expt.
Group
SF
US
SF
US
SF
US
SF
US
SF
US
SF
US

Expt.
Group
SF
US
SF
US
SF
US
SF
US
SF
US
SF
US

Expt.
Group
SF
US
SF
US
SF
US
SF
US
SF
US
SF
US

Baseline
Mean
P value
(SEM)
48.3 (1.9)
NS
51.7 (2.0)
33.5 (1/7)
NS
36.8 (2.0)
63.1 (1.6)
NS
66.7 (1.4)
Recovery
49.7 (1.6)
0.034
44.7 (1.8)
38.0 (1.4)
0.0009
30.4 (1.4)
61.4 (1.6)
NS
59.1 (1.4)
Baseline
Mean
P value
(SEM)
48.9 (1.5)
NS
47.1 (1.7)
39.9 (1.6)
NS
37.5 (1.6)
58.6 (1.8)
NS
57.3 (2.2)
Recovery
52.8 (1.5)
NS
45.7 (1.8)
42.7 (1.6)
NS
34.4 (1.6)
62.9 (1.6)
NS
57.1 (2.2)
Baseline
Mean
P value
(SEM)
50.5 (1.8)
NS
53.3 (1.9)
40.5 (1.7)
NS
42.2 (1.6)
60.5 (1.4)
0.0330
64.3 (1.3)
Recovery
54.7 (4.9)
NS
53.2 (5.1)
42.4 (1.8)
NS
41.0 (2.8)
67.0 (2.5)
NS
65.4 (2.6)

Av. % change
(SF vs US)
-6.6%
-8.8%
-5.5%

Expt.
Group
SF
US
SF
US
SF
US

-11.2%

SF
US
25.3%
SF
US
3.9%
SF
US
SF 3 (11-month-old mice)
Av. % change
(SF vs US)
3.8%
6.4%
2.3%

Expt.
Group
SF
US
SF
US
SF
US

15.5%

SF
US
24.1%
SF
US
10.2%
SF
US
SF 4 (14-month-old mice)
Av. % change
(SF vs US)
-5.3%
-4.0%
-5.9%

2.8%
3.4%
2.4%

Expt.
Group
SF
US
SF
US
SF
US
SF
US
SF
US
SF
US

Week 1 Fragmentation
Mean (SEM)
P value Av. % change
(SF vs US)
46.6 (1.4)
0.0016
-9.1%
51.2 (1.1)
42.8 (1.3)
NS
9.4%
39.1 (1.1)
49.8 (2.3)
<0.0001
-19.2%
61.6 (1.1)
Week 4 Fragmentation
45.4 (1.2)
NS
3.8%
43.7 (1.1)
42.8 (0.9)
<0.0001
30.8%
32.8 (1.0)
47.5 (1/9)
NS
-9.7%
52.5 (1/5)
Week 1 Fragmentation
Mean (SEM)
P value Av. % change
(SF vs US)
40.8 (1.4)
0.008
-13.7%
47.3 (1.3)
41.8 (1.3)
NS
3.0%
40.6 (1.4)
40.0 (2.2)
0.0002
-24.2%
52.8 (1.8)
Week 4 Fragmentation
46.5 (1.4)
NS
2.4%
45.4 (1.2)
42.5 (1.1)
0.03
19.7%
35.5 (1.2)
49.9 (2.3)
NS
-6.9%
53.6 (1.5)
Week 1 Fragmentation
Mean (SEM)
P value Av. % change
(SF vs US)
35.5 (3.2)
<0.0001
-30.9%
51.4 (4.2)
35.4 (1.9)
NS
-18.1%
43.2 (2.9)
36.8 (4.2)
<0.0001
-38.9%
60.2 (2.1)
Week 4 Fragmentation
46.3 (5.3)
NS
-6.3%
49.4 (3.8)
43.8 (2.2)
NS
6.8%
41.0 (2.8)
48.9 (7.2)
<0.0001
-15.3%
57.7 (1.8)

Sleep percentages were not the only sleep measure affected by the SF protocol—sleep
bout duration was altered as well (Table 3), and it showed similar trends to the sleep percentage
data. Remember that rodents sleep in shorter sleep cycles called sleep bouts, and the duration of
these sleep bouts can change based on sleep need. Longer sleep bouts indicate less sleep
fragmentation while shorter sleep bouts indicate more sleep fragmentation. During week 1 of the
SF protocol, sleep bout duration was reduced in SF compared to US mice (significant reductions
in SF 3 and 4, non-significant reduction in SF 2). Again, this is expected as mice are introduced
to the SF intervals where their sleep is being disrupted for four, one-hour intervals during the
light phase. Shorter sleep bout durations indicate that sleep is more fragmented and there are
more frequent awakenings. Again, by week 4 of SF, SF mice are experiencing longer sleep bouts
compared to US mice during the dark phase to make up for their lost sleep during the SF
intervals. However, this is only significant in the youngest SF mice (8 months old, SF 2) and not
significant in the older SF mice (SF 3 and 4). Therefore, younger mice may be better at adjusting
their sleep and increasing their sleep bout lengths during the dark phase in response to the SF
protocol to minimize the amount of fragmentation they are being exposed to. We measured sleep
bout duration and not the number of sleep bouts, so it is possible that the older mice increased
the number of sleep bouts during the dark phase without increasing each sleep bout’s length in
order to make up for their lost sleep, which is supported by the sleep percentage data.
Furthermore, there are interesting results when looking at how the mice’s sleep was
altered during the recovery weekend of rest between weeks 3 and 4 of SF. There appears to be a
trend towards an increase in sleep bout length in the SF mice during the dark phase, however this
is only significant in the 11-month-old mice (SF 3). Additionally, there is a trend towards an
increase in sleep bout length during the light phase in the SF mice, however this is only
significant in the 14-month-old mice (SF 4). Overall, this again shows that during the recovery
weekend, SF mice are attempting to recover their lost sleep through increasing their sleep bout
lengths and possibly the number of sleep bouts (not measured).

Table 3. Sleep Bout Duration for SF 2, 3, and 4.
Values represent mean ± SEM. N=8/group
SF 2 (8-month-old mice)
Sleep Bout
Length
24-hours
Dark phase
Light
phase
24-hours
Dark phase
Light
phase

Sleep Bout
Length
24-hours
Dark phase
Light
phase
24-hours
Dark phase
Light
phase

Sleep Bout
Length
24-hours
Dark phase
Light
phase
24-hours
Dark phase
Light
phase

Expt.
Group
SF
US
SF
US
SF
US
SF
US
SF
US
SF
US

Expt.
Group
SF
US
SF
US
SF
US
SF
US
SF
US
SF
US

Expt.
Group
SF
US
SF
US
SF
US
SF
US
SF
US
SF
US

Baseline
Mean (SEM) P value
374.7 (25.8)
NS
440.1 (29.6)
230.7 (14.4)
NS
269.3 (17.1)
518.7 (26.5)
NS
610.8 (27.3)
Recovery
384.9 (22.1)
NS
317.2 (21.0)
265.1 (13.1)
NS
203.1 (10.5)
504.6 (24.2)
NS
431.3 (23.5)

Av. % change
(SF vs US)
-14.9%
-14.3%
-15.1%

Expt.
Group
SF
US
SF
US
SF
US

SF
US
30.5%
SF
US
17.0%
SF
US
SF 3 (11-month-old mice)

Baseline
Mean (SEM) P value

21.3%

Av. % change
(SF vs US)
3.2%

Expt.
Group
SF
US
SF
US
SF
US

376.0 (18.3)
NS
364.2 (21.7)
305.0 (15.1)
NS
16.0%
263.0 (15.0)
446.9 (26.5)
NS
-4.0%
465.3 (28.5)
Recovery
406.3 (21.7)
0.0471
29.6%
SF
313.5 (21.8)
US
315.6 (19.8)
0.0153
48.3%
SF
212.8 (12.5)
US
496.9 (28.6)
NS
20.0%
SF
414.2 (30.0)
US
SF 4 (14-month-old mice)
Baseline
Mean (SEM) P value Av. % change Expt.
(SF vs US)
Group
362.5 (19.6)
NS
-12.4%
SF
413.6 (23.1)
US
254.1 (13.3)
NS
-13.9%
SF
295.2 (15.8)
US
470.9 (19.4)
NS
-11.5%
SF
531.9 (26.5)
US
Recovery
424.4 (25.9)
NS
7.0%
SF
396.6 (60.9)
US
278.4 (30.4)
NS
5.8%
SF
263.1 (35.4)
US
563.5 (57.9)
0.009
6.8%
SF
527.5 (50.8)
US

Week 1 Fragmentation
Mean (SEM)
P value
Av. % change
(SF vs US)
328.5 (21.3)
NS
-7.5%
355.3 (18.6)
309.4 (15.9)
NS
11.7%
277.0 (11.2)
347.5 (39.6)
NS
-19.9%
433.6 (27.4)
Week 4 Fragmentation
297.0 (14.5)
NS
4.4%
284.5 (13.5)
282.4 (11.9)
0.0434
34.2%
210.4 (8.3)
311.5 (26.5)
NS
-13.1%
358.6 (14.1)
Week 1 Fragmentation
Mean (SEM)
P value
Av. % change
(SF vs US)
273.3 (15.5)
NS
-10.5%
305.4 (12.2)
289.2 (9.8)
NS
4.6%
276.5 (16.7)
257.5 (29.4)
0.0193
-23.0%
334.3 (15.9)
Week 4 Fragmentation
323.9 (22.8)
NS
13.4%
285.7 (15.3)
298.7 (13.0)
NS
28.7%
232.1 (13.3)
349.2 (43.6)
NS
2.9%
339.4 (22.9)
Week 1 Fragmentation
Mean (SEM)
P value
Av. % change
(SF vs US)
250.5 (13.4)
<0.0001
-30.4%
359.9 (15.3)
242.4 (8.7)
NS
-14.3%
282.7 (14.4)
258.6 (25.5)
<0.0001
-40.8%
437.0 (15.3)
Week 4 Fragmentation
279.3 (45.5)
NS
-9.1%
307.1 (42.0)
257.4 (11.6)
NS
11.1%
231.6 (10.3)
321.3 (66.0)
NS
-22.8%
416.1 (101.2)

Effects of SF on Aβ:
SF led to increased levels of Aβ in the hippocampus. In the 8-month-old mice of SF 2,
sleep fragmentation increased the DEA-soluble and RIPA-soluble levels of Aβ40 in the
hippocampus (Figure 2, 3). Also, SF mice had 64% increased levels of RIPA-soluble Aβ42 in
the hippocampus compared to US mice (Figure 2, 3). In the cortex, the only significant result
found was a small increase in the levels of DEA-soluble Aβ40 in the SF compared to US mice—
everything else was insignificant (Figure 3).
In the 11-month-old mice of SF 3, sleep fragmentation increased the RIPA-soluble levels
of Aβ42 in the hippocampus. There was no difference in Aβ40 levels in the hippocampus and no
significant effect in the cortex of these mice (Figure 3).
Finally, in the 14-month-old mice of SF 4, there were no significant differences in the
amount of Aβ found in the hippocampus or cortex in SF compared to US mice. These mice were
very old and had much higher levels of Aβ compared to the younger mice of SF 2 and 3 (Figure
4). There may have been a ceiling effect where Aβ levels were already at their maximum and
could not be further increased by sleep fragmentation.
Figure 2. Chronic sleep fragmentation
increases Aβ levels in the hippocampus
of 8-month-old SF mice. Data show mean
± SEM for N=8/group. #p=0.05, *p<0.05,
**p<0.01, unpaired t-test.

Figure 3. DEA- and RIPAsoluble Aβ levels for SF vs.
US mice in SF 2 (8 months
old) and SF 3 (11 months
old) in the hippocampus
(HIPP) and cortex (CTX).
Data show mean ± SEM for
N=8/group. *p<0.05,
unpaired t-test.

Figure 4. DEA-soluble Aβ40 and Aβ42
levels in mice aged 8 months (SF 2), 11
months (SF 3), and 14 months (SF 4) in
the hippocampus (HIPP) and cortex
(CTX). Data show mean ± SEM for
N=16/age group.

*

Effects of SF on Neuroinflammation:
Sleep fragmentation caused a significant increase in levels of markers of reactive
microglia and trends towards increases in the other markers of neuroinflammation—reactive
astrocytes, inflammatory cytokines, and inflammatory chemokines—in the hippocampus of SF
mice of 8 months of age (SF 2) and 11 months of age (SF 3). 14-month-old mice from SF 4 were
not analyzed for gene expression markers of neuroinflammation. Figure 5A shows Z-scores for
the SF versus US mice’s expression of each specific marker in the four classes of
neuroinflammatory markers measured—a Z-score of 0 represents the mean, or average, levels of
neuroinflammatory markers in all SF 2 and 3 mice analyzed (N=30); therefore, a positive Zscore indicates that the mice are expressing higher than average levels of neuroinflammatory
markers while a negative Z-score indicates that the mice are expressing lower than average levels
of neuroinflammatory markers. Consequently, one can tell from Figure 5A that SF mice are
expressing higher levels of each marker of all four classes of neuroinflammatory markers
(positive Z-scores) in comparison to the US mice (negative Z-scores). A composite Z-score of
the three inflammatory markers in each class uncovered a significant effect of SF on increased
expression of reactive microglia (Figure 5B). There was also a trend towards an increase in the
three kinds of proinflammatory cytokines expressed in the SF compared to US groups, however
this was not significant at a p-value of 0.058 (Figure 5B). Finally, there were no significant
differences in any of the four classes of gene expression markers of neuroinflammation in the
cortex between SF and US mice at 8 months and 11 months of age.

A

B

Figure 5. Effects of SF on mRNA
neuroinflammatory marker
expression in the hippocampus.
4 classes of neuroinflammatory
markers were measured in the SF
(N=16) and US (N=14) groups. (A)
shows Z-scores for each of the
markers while (B) shows
composite Z-scores of each of
the three neuroinflammatory
markers in its class (4 total
classes).

Discussion:
This study aimed to determine the effects of fragmentation of the daily sleep-wake
rhythm on levels of Aβ and gene expression markers of neuroinflammation in the brains of
female 3xTg-AD mice. The 3xTg-AD mice model AD in humans, and they have three mutations
that result in the formation of Aβ plaques and neurofibrillary tangles (Oddo et al., 2003). Many
humans suffering from Alzheimer’s disease have sleep disorders and disrupted sleep-wake
cycles, resulting in fragmented sleep during the night and sleepiness during the day (Ju et al.,
2013; Peter-Derex et al., 2015; Holth et al., 2017). We completed three pilot studies that aimed
to explore a possible causal relationship between sleep and AD in greater detail and see if
disruption of the daily sleep-wake cycle via sleep fragmentation can actually lead to the
progression of AD-like neuropathological changes. To disrupt the daily sleep-wake cycle of the
mice, we subjected them to a SF protocol that involved 4 one-hour-long SF sessions during the
light phase, 5 days a week, for 4 weeks. The SF mice were kept awake during these SF intervals
by placing novel toys in their cages and lightly tapping the mice with paintbrushes while leaving
the US mice undisturbed and allowed to sleep normally. We decided to disrupt their sleep in this
manner as opposed to sleep depriving the mice for several straight hours because our protocol
more closely mirrors the fragmentation of sleep in humans with AD. Mice normally sleep more
during the light phase and less during the dark phase, so our SF intervals during the light phase
in mice closely match the frequent awakenings that human AD patients have throughout the
night.
The SF protocol altered the daily distribution of sleep and wakefulness. SF mice slept
significantly less during the SF intervals from 9:00-10:00 am, 11:30 am-12:30 pm, 2:00-3:00 pm,
and 4:30-5:30 pm compared to US mice that were free to sleep as expected during these
intervals. In the first week of SF, the SF intervals caused SF mice to have significantly less sleep
in the light phase compared to US mice. As a result, the SF mice slept less across 24 hours
compared to US mice. This mimics how human AD patients often exhibit less total daily sleep
due to frequent nighttime awakenings (Peter-Derex et al., 2015). However, by the recovery
weekend and fourth week of each study, the SF mice had adapted to the protocol by altering the
daily distribution of their sleep and wakefulness. The SF mice slept more than the US mice
during the inter-fragmentation intervals, which were the times during the light phase between the
SF intervals. This increase in sleep immediately following SF intervals was the SF mice’s way of
making up for that lost sleep, which resulted in total light phase sleep between SF and US mice
to be not significantly different by week 4, especially in the younger mice of SF 2 and 3. Older
mice of SF 4 exhibited this trend, but couldn’t quite adjust their sleep schedules as successfully,
resulting in some data that was not significant. Additionally, by the recovery weekend and fourth
week of each study, the SF mice were sleeping more than the US mice during the dark phase;
again, this increase in dark phase sleep was a way for SF mice to make up for their lost sleep
incurred from the SF protocol. This mirrors human AD patients experiencing daytime sleepiness
and taking naps during their active period to make up for lost sleep at night (Ju et al., 2013).
Thus, our experiments illustrate that AD-like neuropathological changes occurred due to altered
sleep patterns from the sleep fragmentation protocol, and not because of mice getting less total
24-hour sleep. This is interesting because previous studies have shown that fragmentation of the

daily sleep-wake rhythm even without loss of total sleep is associated with increased risk of AD
(Lim et al., 2013). Furthermore, it was interesting that the youngest SF mice of SF 2 even had
increased sleep bout lengths in the dark phase by week 4 of the study, indicating that they were
sleeping for longer periods of time with less fragmentation during their normally active phase to
make up for lost sleep. Overall, the younger SF mice of SF 2 and 3 were better able to alter their
daily distribution of sleep and wakefulness in response to the SF protocol compared to the older
mice of SF 4 experiencing sleep fragmentation. This mirrors how as AD progresses in older
human patients, sleep disturbances get worse (Ju et al., 2013). On the other hand, the undisturbed
mice of each study continued sleeping “normally,” with about 60-70% of their sleep occurring in
the light phase and 30-40% occurring during the dark phase.
Furthermore, 3xTg-AD mice (of SF 2 and 3) exposed to sleep fragmentation exhibited
significantly higher levels of Aβ in the hippocampus. SF especially induced large increases in the
amount of RIPA-soluble Aβ in the hippocampus, which is the less soluble kind of Aβ often
responsible for plaques. This suggests that Aβ is building up in the hippocampus and aggregating
in response to the SF protocol, increasing the amount of RIPA-soluble Aβ more than DEAsoluble Aβ, which measures smaller Aβ monomers. Likewise, Aβ42, which is the more
neurotoxic form of Aβ, increased even more than Aβ40 in SF mice. Older mice of SF 4 did not
show significant increases in Aβ in response to sleep fragmentation; however, these older mice
already exhibited such high levels of Aβ by the time they were euthanized that a ceiling effect is
likely. Moreover, the hippocampus plays a large role in learning and memory, so it makes sense
that Aβ would accumulate in the hippocampus in AD, eventually leading to the characteristic
symptoms of memory loss and cognitive decline. It is also possible that the hippocampus is very
sensitive to altered sleep-wake rhythms, resulting in the higher levels of Aβ found in the
hippocampus after SF. There were no changes in the amount of Aβ found in the cortex following
sleep fragmentation in all three pilot studies. Perhaps the cortex is not as sensitive to sleep
fragmentation as the hippocampus is, or maybe the studies needed to last longer to see an effect
in the cortex. The cortex is responsible for many functions, including storing long-term
memories after the hippocampus creates these memories. The cortex has been shown to atrophy
in AD patients at later stages than the hippocampus, which shows neuropathological changes
much earlier (Schachter and Davis, 2000). Because the hippocampus is responsible for shortterm memory formation, this also may explain why many AD patients show short-term memory
impairment early in their disease progression and lose the ability to remember what day it is or
what they ate for breakfast, for example. On the other hand, many early-stage AD patients still
have intact long-term memories from their childhoods since this information is stored in the
cortex. Therefore, our studies suggest that SF will interfere with short-term memory while
having less effect on long-term memory.
3xTg-AD mice (of SF 2 and 3) exposed to sleep fragmentation exhibited significantly
higher levels of neuroinflammatory markers of reactive microglia, and increasing trends in the
other 3 classes—reactive astrocytes, proinflammatory cytokines, and inflammatory
chemokines—in the hippocampus. Similar to Aβ, this effect was not seen in the cortex. It is
possible that the increased levels of Aβ caused overactivation and increased expression of

microglia in the hippocampus, resulting in increased neuroinflammation. In humans, this cascade
would lead to cell death, synapse loss, and neurodegeneration.
In conclusion, these findings that disruption of the daily sleep-wake cycle with sleep
fragmentation increases Aβ levels and expression of neuroinflammatory markers in the
hippocampus of 3xTg-AD mice have many important implications. Increases in Aβ levels and
expression of neuroinflammatory markers can lead to the progression of AD and worsening of
symptoms as more cells die and synapses degrade. While some studies have looked at prolonged
sleep deprivation (Qiu et al., 2016; Kang et al., 2009; Kincheski et al., 2017), our version of
sleep fragmentation more closely mirrors the altered sleep-wake cycles of human AD patients,
and may serve as a better model for sleep disruption in the disease. These findings indicate a
strong link between sleep and AD in that sleep can have causal effects on the progression of ADlike neuropathological changes. Future studies should investigate whether sleep consolidation
could be a potential therapeutic strategy for reducing the progression of AD neuropathology in
humans.
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